{"nctId":"NCT00309777","briefTitle":"Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin","startDateStruct":{"date":"2005-09"},"conditions":["Hypercholesterolemia","Dyslipidemia"],"count":857,"armGroups":[{"label":"Pitavastatin 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pitavastatin"]},{"label":"Simvastatin 20 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin"]},{"label":"Pitavastatin 4 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Pitavastatin"]},{"label":"Simvastatin 40 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Simvastatin"]}],"interventions":[{"name":"Pitavastatin","otherNames":[]},{"name":"Simvastatin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females (18-75 years)\n* Must have been following a restrictive diet\n* Diagnosis of primary hypercholesterolemia or combined dyslipidemia\n\nExclusion Criteria:\n\n* Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia;\n* Conditions which may cause secondary dyslipidemia.\n* Uncontrolled diabetes mellitus (by hemoglobin A1c \\[HbA1c\\] \\> 8%)\n* Abnormal serum creatine kinase (CK) above the pre-specified level\n* Abnormal pancreatic, liver or renal function\n* Significant heart disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks","description":"Percent change from baseline in low density lipoprotein-cholesterol (LDL-C)after 12 Weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.99","spread":"14.573"},{"groupId":"OG001","value":"-34.97","spread":"15.528"},{"groupId":"OG002","value":"-43.97","spread":"14.494"},{"groupId":"OG003","value":"-42.84","spread":"15.769"}]}]}]},{"type":"SECONDARY","title":"National Cholesterol Education Program (NCEP) LDL-C Target Attainment","description":"Number of subjects achieving National Cholesterol Education Program (NCEP) LDL-C Target (LDL less than or equal to 130 mg/dL)at Week 12","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"215","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"253","spread":null},{"groupId":"OG003","value":"86","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":311},"commonTop":["Headache","Myalgia","Diarrhea","Back pain","Nausea"]}}}